Molsidomine--an effective antianginal drug. Results of an acute randomized stress-testing study.
The antianginal efficacy of molsidomine (single oral dose of 2 mg), a new antianginal drug, was evaluated in 12 patients with coronary artery disease in a double-blind randomized placebo-controlled study by bicycle ergometry. Besides the standard ergometric parameters, the myocardial efficiency index (MEI) was determined from the ratio of the maximum workload (kgm/min) to double product (mm Hg X min) X 10(-2), normalized for body surface area. Compared to placebo, molsidomine decreased positive exercise tests by 50%, pain response by 66%, and the magnitude of ST depression by 43%. Furthermore, the onset of ergometric positive response was delayed, with an increase in maximum workload achieved (+21%), total work performed (+43%), and duration of exercise (+28%). MEI also increased from 0.98 +/- 0.43 to 1.18 +/- 0.44 (p less than 0.005), due to a significant increase in maximal workload without a parallel increase in double product. These findings suggest that molsidomine is an effective antianginal drug and improves myocardial efficiency in patients with angina due to coronary artery disease.
D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D008981:Molsidomine; D009203:Myocardial Infarction / Q000150:complications; D009206:Myocardium / Q000378:metabolism; D010069:Oxadiazoles / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects; D011897:Random Allocation; D013558:Sydnones / Q000627:therapeutic use*
D010069:Oxadiazoles; D013558:Sydnones; D008981:Molsidomine